Erasca
pivotal phase and phase trial designs capitalize on promising efficacy signals and support potential successful registration in multiple indications setae dor secondary | Erasca
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
21 of 41
Related slides by other companies
Dare Bioscience
Investor Presentation
February 2023
advancing products women want the portfolio snapshot | Dare Bioscience
BioAtla
Investor Presentation
August 2023
phase study design with | BioAtla
23andMe
Investor Presentation
April 2023
phase a study of me in patients with locally advanced or metastatic solid malignancies | 23andMe
NeuroSense Therapeutics
Investor Presentation
December 2023
phase study results achieved primary with a safety and tolerability profile comparable to placebo | NeuroSense Therapeutics
Other recent decks by Erasca
See all presentations (4 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
IPO
July 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io